Prunella Vulgaris Flower

Dosage for Prunella Vulgaris Flower extract is highly individualized and depends entirely on the patient's level of sensitivity as determined by clinical history and skin test results.

Diagnostic Testing

• Percutaneous (Scratch, Prick, or Puncture) Testing: Usually, one drop of the 1:10 or 1:20 w/v extract is applied to the skin, followed by a prick or puncture through the drop. A positive result is a wheal at least 3mm larger than the negative control.
• Intradermal Testing: If percutaneous tests are negative, a dose of 0.02 to 0.05 mL of a much more dilute solution (e.g., 1:1000 w/v) may be injected into the dermis.

Immunotherapy

• Build-up Phase: Treatment typically begins with a very low dose (e.g., 0.05 mL of a 1:100,000 w/v dilution) injected subcutaneously once or twice a week. The dose is gradually increased based on the patient's local reaction and tolerance.
• Maintenance Phase: Once the target maintenance dose is reached (often 0.5 mL of a 1:100 or 1:10 w/v dilution), the interval between injections is increased to every 2 to 4 weeks.

Prunella Vulgaris Flower extract may be used in children, but extreme caution is required. Dosing follows the same weight/volume principles as adult dosing but must be adjusted based on the child's smaller skin surface area for testing and potentially higher sensitivity. Safety and efficacy in children under the age of 5 have not been extensively established, and the risk-benefit ratio must be carefully considered by a pediatric allergist.

Renal Impairment

No specific dosage adjustments are typically required for renal impairment, as the systemic protein load is minimal. However, patients with severe renal disease may have altered skin reactivity.

Hepatic Impairment

No specific adjustments are required. The metabolism of these proteins is not primarily dependent on hepatic CYP450 enzymes.

Elderly Patients

Elderly patients may exhibit reduced skin reactivity (false negatives) due to age-related changes in skin turgor and mast cell density. Lower starting doses in immunotherapy are often recommended due to the higher prevalence of comorbid cardiovascular conditions in this population.

This medication is never self-administered. It must be administered by a healthcare professional in a clinical setting equipped with emergency resuscitation equipment.

• Skin Testing: The skin (usually the forearm or back) is cleaned with alcohol. The extract is applied, and the skin is pricked. Results are read exactly 15 to 20 minutes later.
• Immunotherapy: Injections are given subcutaneously, usually in the posterior aspect of the upper arm. The injection site should not be massaged.
• Storage: Extracts must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

In immunotherapy, if a dose is missed, the next dose may need to be reduced depending on how much time has passed. If the interval exceeds the recommended schedule by more than one week, the physician may revert to a previous lower dose to prevent an adverse reaction.

An overdose of allergenic extract can lead to severe systemic reactions, including generalized urticaria, angioedema, bronchospasm, and anaphylactic shock.

• Signs: Rapid onset of itching, flushing, shortness of breath, or a drop in blood pressure.
• Emergency Measures: Immediate administration of epinephrine (1:1000) intramuscularly, followed by antihistamines, corticosteroids, and intravenous fluids as needed. The patient must be monitored for at least several hours for late-phase reactions.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

The most frequent side effects associated with Prunella Vulgaris Flower extract are localized to the site of administration.

• Local Wheal and Flare: A raised, red, itchy bump at the test or injection site. This is an expected result during diagnostic testing and a common minor side effect during immunotherapy. It usually resolves within 1 to 2 hours.
• Local Swelling: During immunotherapy, swelling at the injection site (larger than a half-dollar) may occur. This can feel warm or tender and may last for 24 to 48 hours.
• Pruritus (Itching): Intense itching at the site of administration is very common.

• Delayed Local Reactions: Swelling and redness that appear 6 to 24 hours after administration. These are often treated with cold compresses and oral antihistamines.
• Headache: Some patients report mild headaches following immunotherapy sessions.
• Fatigue: A general feeling of tiredness or malaise shortly after receiving an injection.
• Nasal Congestion: Mild sneezing or stuffy nose may occur as part of a minor systemic response.

• Generalized Urticaria: Hives appearing on parts of the body far from the injection site.
• Angioedema: Significant swelling of the lips, eyelids, or extremities.
• Persistent Lymphadenopathy: Swelling of the lymph nodes near the injection site.

> Warning: Stop taking Prunella Vulgaris Flower and call your doctor immediately if you experience any of these.

• Anaphylaxis: This is a life-threatening emergency. Symptoms include a sudden drop in blood pressure (fainting), rapid or weak pulse, narrowing of the airways (wheezing), and nausea/vomiting.
• Bronchospasm: Sudden constriction of the muscles in the walls of the bronchioles, causing severe difficulty breathing.
• Laryngeal Edema: Swelling of the throat that can block the airway.
• Hypotension: A dangerous drop in blood pressure that can lead to shock.

With prolonged immunotherapy, some patients may develop 'serum sickness-like' symptoms, including joint pain and fever, although this is extremely rare with modern extracts. There is also a theoretical risk of developing new sensitivities to other components in the extract, though the clinical goal is the opposite (tolerance).

While non-standardized extracts may not always carry a formal 'Black Box' in the same format as tablets, the FDA-approved labeling for all allergenic extracts contains a Boxed Warning regarding the risk of severe systemic reactions.

Summary of Warning: Prunella Vulgaris Flower extract can cause severe life-threatening systemic reactions, including anaphylaxis. Patients must be observed for at least 30 minutes after administration in a facility equipped with emergency supplies, including epinephrine. Patients with unstable asthma are at increased risk for severe reactions.

Report any unusual symptoms to your healthcare provider.

Prunella Vulgaris Flower extract is intended for use only by physicians who are experienced in the administration of allergenic extracts and the management of allergic emergencies. Because of the risk of systemic reactions, patients must remain in the doctor's office for a minimum of 30 minutes following any injection or skin test.

No FDA black box warnings for Prunella Vulgaris Flower specifically exist in the same way they do for high-risk pharmaceuticals like opioids, but the class-wide Boxed Warning for Allergenic Extracts is applicable. It emphasizes that these products can cause anaphylaxis and should only be used in settings where emergency resuscitation is immediately available. It also notes that the potency of non-standardized extracts can vary between lots, increasing the risk of reaction when switching vials.

• Anaphylaxis Risk: Any patient receiving Prunella Vulgaris Flower extract must be screened for factors that increase the risk of a fatal reaction. This includes poorly controlled asthma or the use of certain medications like beta-blockers.
• Asthma Exacerbation: Patients experiencing an acute asthma flare-up should not receive allergenic extracts until their asthma is stabilized, as they are at a much higher risk for a severe systemic reaction.
• Cardiovascular Disease: Patients with significant heart disease may be less able to tolerate the physiological stress of a systemic reaction or the effects of epinephrine if it becomes necessary.

• Pre-Injection Assessment: The clinician must assess the patient for any new illnesses or changes in asthma status before every dose.
• Post-Injection Observation: Mandatory 30-minute observation to monitor for signs of systemic reaction (e.g., coughing, itching, flushing).
• Peak Flow Monitoring: For asthmatic patients, a peak flow meter may be used before and after administration to ensure airway stability.

Generally, Prunella Vulgaris Flower extract does not interfere with the ability to drive. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive until cleared by a physician.

Alcohol should be avoided on the day of an injection or skin test. Alcohol can cause vasodilation, which may potentially increase the rate of allergen absorption and exacerbate a systemic reaction.

Immunotherapy with Prunella Vulgaris Flower is usually discontinued if the patient fails to show clinical improvement after 12-24 months of maintenance therapy, or if the patient experiences repeated severe systemic reactions that cannot be managed by dose adjustment.

> Important: Discuss all your medical conditions with your healthcare provider before starting Prunella Vulgaris Flower.

• Beta-Blockers (e.g., Propranolol, Atenolol): These are strictly contraindicated or used with extreme caution. Beta-blockers can increase the severity of an anaphylactic reaction and, more importantly, can make the reaction resistant to the standard doses of epinephrine used for treatment.

• ACE Inhibitors (e.g., Lisinopril): These may increase the risk of systemic reactions or more severe hypotension during an allergic event.
• MAO Inhibitors (e.g., Phenelzine): Can potentiate the effect of epinephrine if it needs to be administered, potentially leading to a hypertensive crisis.

• Antihistamines (e.g., Cetirizine, Diphenhydramine): These medications will suppress the skin's response to the extract, leading to false-negative diagnostic results. They must be discontinued for several days (usually 3-7 days) prior to skin testing.
• H2 Blockers (e.g., Famotidine): May also mildly suppress skin test reactivity.
• Tricyclic Antidepressants (e.g., Amitriptyline): These possess potent antihistamine activity and can interfere with skin test results for weeks.

There are no direct food interactions with Prunella Vulgaris Flower extract. However, patients should avoid heavy meals immediately before or after an injection to ensure that any gastrointestinal symptoms of anaphylaxis (like nausea) are not confused with simple indigestion.

• St. John's Wort: May theoretically affect the immune response, though no clinical data confirms this.
• High-dose Vitamin C: Some studies suggest Vitamin C has mild antihistamine properties which could theoretically interfere with skin test accuracy.

Prunella Vulgaris Flower extract does not interfere with standard blood chemistry or hematology tests. However, it will directly affect the results of:

• Skin Prick Tests: As intended.
• Serum IgE Testing (ImmunoCap): The presence of the extract in the body during immunotherapy may eventually lead to a decrease in specific IgE levels over several years.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Previous Severe Systemic Reaction: Patients who have experienced life-threatening anaphylaxis to Prunella Vulgaris Flower extract in the past should generally not receive it again.
• Severe, Uncontrolled Asthma: Patients with an FEV1 (Forced Expiratory Volume) consistently below 70% of predicted values are at an unacceptably high risk for fatal bronchospasm during a reaction.
• Acute Infection or Fever: Administration should be delayed until the patient is well, as an active immune system may be more prone to overreacting to the extract.

• Pregnancy: While not a strict contraindication, initiating new immunotherapy during pregnancy is generally avoided due to the risk of maternal anaphylaxis causing fetal hypoxia. Maintenance therapy may be continued if well-tolerated.
• Autoimmune Disorders: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis may experience a flare-up of their condition due to the immune stimulation caused by the extract.
• Malignancy: Patients with active cancer are generally not candidates for immunotherapy as the immune system is already compromised or hyper-focused on the malignancy.

Patients allergic to Prunella Vulgaris Flower may show cross-sensitivity to other members of the Lamiaceae family, including:

• Mentha (Mint)
• Salvia (Sage)
• Lavandula (Lavender)
• Origanum (Oregano)

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Prunella Vulgaris Flower.

Prunella Vulgaris Flower extract is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. The primary concern during pregnancy is the risk of a systemic allergic reaction (anaphylaxis) in the mother, which can lead to a sudden drop in blood pressure and uterine hypoperfusion, potentially causing fetal distress or death. Most allergists recommend against starting new immunotherapy during pregnancy but may continue maintenance doses if the patient is stable and the benefit outweighs the risk.

It is not known whether the allergenic proteins from Prunella Vulgaris Flower extract are excreted in human milk. Because many proteins are digested in the infant's gut, the risk to a nursing infant is considered low. However, the decision to continue immunotherapy while breastfeeding should be made in consultation with a healthcare provider, considering the mother's need for treatment.

As noted, the safety and efficacy of allergenic extracts in children under age 5 have not been established. In older children, the extract is generally safe when administered by a specialist. Children may be more prone to large local reactions, and their inability to clearly communicate early symptoms of a systemic reaction (like an 'itchy throat') requires extra vigilance from the clinical staff.

Clinical studies of Prunella Vulgaris Flower extract did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased cardiac function and concomitant drug therapy (especially beta-blockers or ACE inhibitors).

No specific studies have been conducted in patients with renal impairment. Since the extract consists of proteins that are naturally degraded into amino acids, renal clearance of the intact allergen is not a major pathway. However, uremia in severe renal failure can suppress skin reactivity, potentially leading to false-negative diagnostic tests.

No studies have been conducted in patients with hepatic impairment. Hepatic metabolism is not a primary route of elimination for allergenic extracts, so dose adjustments based on Child-Pugh classification are not standard.

> Important: Special populations require individualized medical assessment.

Prunella Vulgaris Flower extract acts as an exogenous antigen. In diagnostic use, it facilitates the Type I Hypersensitivity Reaction. Upon contact with the skin's mast cells, the allergens in the extract (which include various proteins and glycoproteins) bind to specific IgE antibodies. This binding causes the IgE receptors (FcεRI) to aggregate, triggering a signal transduction pathway involving tyrosine kinases. This results in the release of pre-formed mediators like histamine and the synthesis of new mediators like leukotriene C4. These substances act on H1 receptors on vascular smooth muscle and endothelial cells, causing the characteristic wheal (edema) and flare (erythema).

In immunotherapy, the mechanism is complex and involves 'immune deviation.' It induces the production of T-regulatory cells that secrete IL-10 and TGF-beta, which suppress the allergic Th2 response. It also promotes the production of IgG4, which acts as a 'blocking antibody' by competing with IgE for allergen binding, thereby preventing mast cell degranulation.

• Onset of Action: Skin test reactions typically peak at 15-20 minutes.
• Duration of Effect: The visible skin reaction usually subsides within 2 hours, though a late-phase reaction (mediated by eosinophils and T-cells) can occur 6-12 hours later.
• Tolerance: Immunological tolerance (the goal of immunotherapy) typically requires 3-5 years of consistent treatment.

| Parameter | Value |

|---|---|

| Bioavailability | <1% (Percutaneous); ~100% (Subcutaneous injection) |

| Protein Binding | N/A (Biological extract) |

| Half-life | Variable (Proteins degraded within hours/days) |

| Tmax | 15-20 minutes (Skin reaction) |

| Metabolism | Proteolysis by tissue and plasma proteases |

| Excretion | Renal (as amino acids/peptides) |

The extract is a complex mixture. Key chemical constituents of the Prunella vulgaris flower include Rosmarinic acid, Ursolic acid, Oleanolic acid, and various polysaccharides and tannins. The molecular weight of the allergenic proteins typically ranges from 10 kDa to 70 kDa. It is soluble in aqueous buffers and stabilized in 50% glycerin.

Prunella Vulgaris Flower belongs to the Non-Standardized Plant Allergenic Extract [EPC] class. Related medications include other non-standardized extracts like Goldenrod, Dandelion, and various tree or grass pollens.